Curi RMB Capital LLC Has $1.61 Million Stake in Pfizer Inc. (NYSE:PFE)

Curi RMB Capital LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 4.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 55,770 shares of the biopharmaceutical company’s stock after purchasing an additional 2,487 shares during the period. Curi RMB Capital LLC’s holdings in Pfizer were worth $1,614,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Addison Advisors LLC increased its holdings in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock worth $1,512,000 after buying an additional 41,668 shares during the last quarter. KBC Group NV increased its holdings in shares of Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after purchasing an additional 639,985 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Pfizer by 4.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock valued at $379,657,000 after purchasing an additional 544,418 shares during the last quarter. LGT Group Foundation increased its holdings in shares of Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after purchasing an additional 18,274 shares during the last quarter. Finally, Radnor Capital Management LLC acquired a new position in shares of Pfizer in the third quarter valued at $2,972,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Down 4.7 %

PFE opened at $24.80 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a 50-day simple moving average of $28.71 and a 200 day simple moving average of $28.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $140.54 billion, a price-to-earnings ratio of 33.51, a P/E/G ratio of 0.85 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.77%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.